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Background: Published criteria deﬁning the accelerated phase in chronic myeloid leukemia
are  heterogeneous and little is known about predictors of poor outcome.
Methods: This is a retrospective study of 139 subjects in the accelerated phase of chronic
myeloid leukemia treated with imatinib at a single center in Brazil. The objective was
to  identify risk factors for survival, major cytogenetic response and progression to blast
phase  in this population. The factors analyzed were: blasts 10–29%, basophils ≥ 20%,
platelets > 1 × 106/L or <1 × 105/L and white blood cells > 1 × 105/L in the peripheral blood,
as  well as clonal evolution, splenomegaly, hemoglobin < 10 g/dL, time between diagnosis of
chronic myeloid leukemia and imatinib treatment, and hematologic toxicity.
Results: Risk factors for poor survival in multivariate analysis were Grades 3–4 hema-
tologic toxicity (p-value = 0.001), blasts 10–29% (p-value = 0.023), and hemoglobin < 10 g/dL
(p-value = 0.04). Risk factors for not achieving major cytogenetic response were blasts 10–29%
(p-value = 0.007), hemoglobin < 10 g/dL (p-value = 0.001), and previous use of interferon (p-
value = 0.032). Risk factors for progression to the blast phase were hemoglobin < 10 g/dL
(p-value = 0.005), basophils ≥ 20% (p-value = 0.023), and time from diagnosis of chronic
myeloid leukemia to imatinib treatment > 12 months (p-value = 0.030).
Conclusion: These data indicate that patients with the above risk factors have a worse prog-
nosis. This information can guide the therapy to be used.©  2015 Associac¸ão Bra
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Introduction
Chronic myeloid leukemia (CML) is a clonal disorder of
hematopoietic stem cells characterized by the reciprocal
translocation t(9;22)(q34;q11) which determines the Philadel-
phia chromosome and constitutive activation of the break-
point cluster region-Abelson (BCR-ABL) tyrosine kinase.1,2 At
the time of diagnosis, 90% of patients are in the chronic phase
(CP). However, CML  can progress from the CP to a more  aggres-
sive clinical picture – the accelerated phase (AP), when disease
control is more  difﬁcult. AP is a signal of progression and trans-
formation to the usually fatal blast phase (BP).
Over the past decade, the introduction of imatinib mesy-
late has been considered the ﬁrst-line therapy for all phases
of CML.3–7 Clinical trials have established the efﬁcacy of imat-
inib in targeting the pathophysiology of CML, resulting in
increased survival and fewer side effects than with the use
of interferon.8–10 In Brazil, the delayed approval of imatinib
mesylate for ﬁrst line therapy led many  patients to receive
this therapy only at advanced phases of the disease. In the era
of tyrosine kinase inhibitors, it is important to deﬁne progno-
stic factors not only prior to therapy but also during the course
of treatment. The biological characteristics of the disease can
strongly inﬂuence the degree and duration of response to
imatinib and the overall survival (OS).
The criteria of the AP vary in the literature (Table 1). While
some criteria are included in most classiﬁcations, such as per-
centage of basophils and blasts in the peripheral blood (PB),
others are subjective and are included in only some classiﬁca-
tions, e.g. persistent splenomegaly. The International Blood
and Marrow Transplant (IBMTR) criteria have been used in
studies that involved bone marrow transplantation.11 In 2001
the World Health Organization (WHO) proposed a new classi-
ﬁcation system in order to reﬁne the criteria for the AP and
BP.12 In 2006, the MD  Anderson Cancer Center reclassiﬁed
patients and compared their outcomes with imatinib as well,
based on standard deﬁnitions and on the new WHO  classiﬁca-
tion system.6 The European Leukemia net (ELN) criteria were
revised in 2013.13
Objective
The main purpose of this study was to identify which risk fac-
tors were associated with poor survival, with the lack of major
cytogenetic response (MCR), and with progression to BP in a
Brazilian AP-CML population from a single referral center.
Methods
This retrospective study, performed from January 2000 to
November 2011, comprised 139 patients with AP-CML who
were treated with imatinib at the hematopoietic stem cell
transplant (HSCT) center of Hospital de Clínicas of the Uni-
versidade Federal do Paraná, Brazil. The WHO  criteria are
routinely used to evaluate patients with AP-CML at this center.
However, as the objective of this study was to do an exploratory
analysis of published risk factors, subjects were categorized
with AP-CML if they had at least one of the aforementioned 2 0 1 5;3  7(5):341–347
published criteria.6,11–13 All patients received imatinib at an
initial dose of 600 mg  as ﬁrst therapy for AP-CML. Doses were
incremented (maximum of 800 mg)  in cases of inadequate
response or reduced (minimum of 300 mg)  in cases of hemato-
logical or non-hematological toxicity, as necessary. This study
was approved by the Ethics Committee of Hospital de Clínicas,
Universidade Federal do Paraná, which waived the require-
ment of informed consent, as this was a retrospective study
with collection of data from medical records.
The following risk factors, some of which were selected
according to previously published criteria (Table 1), were
evaluated: basophils ≥ 20% in PB, platelets > 1000 × 109/L unre-
sponsive to therapy or <100 × 109/L in PB, white blood cells
(WBC) >100 × 109/L in PB, blast 10–29% in PB, presence of
clonal evolution (CE), hemoglobin <10 g/dL, and splenomegaly.
Splenomegaly was considered when the spleen was palpable
≥10 cm from the left costal margin despite the use of hydrox-
yurea. Other clinical factors relevant to the disease were also
analyzed, including the Sokal score > 0.8 (calculated at the
time of diagnosis), time between diagnosis of CML and treat-
ment with imatinib > 12 months, previous use of interferon,
age > 60 years, and Grades 3–4 hematologic toxicity.
As the PB blasts cut-off point varies in the existing criteria,
this study analyzed PB blasts as a continuum with death as
the endpoint. A receiver operating characteristic (ROC) curve
with death as the endpoint was designed to identify a cut-off
value for the PB blast count.
Cytogenetic analysis was performed by the G-banding
technique. Bone marrow specimens were examined on direct
short-term (24-h) cultures with at least 20 metaphases being
analyzed. BCR-ABL transcripts were detected by analyzing
peripheral blood with quantitative real-time polymerase chain
reaction (PCR) according to the International Scale.
Statistic analyses were performed using the STATA pro-
gram version 8.0. Bivariate and multivariate analyses were
performed using the Cox proportional hazards regression
model. Variables with p-values < 0.20 in the bivariate anal-
ysis were included in the multivariate analysis model. A
p-value < 0.05 was considered statistically signiﬁcant. Disease
free survival (DFS) was deﬁned as the time from the beginning
of treatment to loss of MCR.
The primary endpoint of this study was the identiﬁcation
of risk factors for survival. Risk factors for lack of MCR  and
transformation to BP were evaluated as secondary endpoints.
The BP considered PB or marrow blasts ≥30%.
Results
One hundred and sixty-three patients in AP-CML were identi-
ﬁed. Twenty-four patients treated with dasatinib or nilotinib
were excluded. Thus, 139 AP-CML patients were treated with
imatinib. Of these 139 patients, 60 (43.2%) patients who  pre-
sented at this center with AP had only received hydroxyurea
previously. The remaining 79 (56.8%) patients progressed from
CP CML  treated mainly with hydroxyurea or interferon alpha
in isolation or with Ara-C. Of the 139 patients included, 62
(44.6%) were female and 77 (55.4%) were male. Median age
was 43.6 years and 25 (18%) were >60 years of age. Forty-
one patients (29.5%) died during the study follow-up and 22
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Table 1 – List of the criteria deﬁning accelerated phase chronic myeloid leukemia as recommended by MDACC,6 IBMTR,11
WHO12 and ELN.13
Criteria MDACC IBMTR WHO ELN
Blasts PB or BM 10–29% PB or BM ≥ 10% PB or BM 10–19% PB or BM 15–29%
Blasts and promyelocytes ≥30% PB or BM ≥ 20% NA ≥30% with
blasts < 30%
Basophils PB or BM ≥ 20% PB ≥ 20% PB ≥ 20% PB ≥ 20%
Platelets >1000 × 109/L, or
<100 × 109/L,
unresponsive to
therapy
Persistent
thrombocytosis
>1000  × 109/L, or
<100 × 109/L,
unresponsive to
therapy
Persistent throm-
bocytopenia
(<100 × 109/L)
unrelated to
therapy
WBC >10 × 109/L Difﬁcult control Increasing WBC
count
unresponsive to
therapy
NA
Anemia NA Unresponsive to
therapy
NA  NA
Splenomegaly Persistent
splenomegaly
unresponsive to
sustained
therapy
Increasing
spleen size
Increasing
spleen size
NA
Cytogenetic NA CE CE not present at
the time of
diagnosis
Clonal
chromosome
abnormalities in
Ph+ cells
(CCA/Ph1), major
route, on
treatment
Others Myeloﬁbrosis,
chloromas
Large  foci or
clusters of blasts
in bone marrow
biopsy
MDACC: M. D. Anderson Cancer Center; IBMTR: International Blood and Marrow Transplant Registry; WHO: World Health Organization; ELN:
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10 g/dL (p-value = 0.033), age > 60 (p-value = 0.080), and time
from CML  diagnosis to treatment with imatinib > 12 months
(p-value = 0.018). In forward multivariate analysis, only Grades
Table 2 – Characteristics of the 139 accelerated phase
chronic myeloid leukemia patients.
Variable
Gender, male/female, n (%) 77/62 (55.4/44.6)
Age (years), median (range) 43.6 (10–78)
Previous therapy
Interferon, n (%) 64 (46.0)
Hydroxyurea, n (%) 60 (43.2)
Others, n (%) 15 (10.8)
Hemoglobin < 10 g/dL, n (%) 28 (20.14)
Platelets > 1000 × 109/L or <100 × 109/L, n (%) 29 (21.86)
Spleen ≥ 10 cm from left costal margin, n (%) 38 (27.34)
PB blasts 10–29%, n (%) 13 (9.35)
PB basophils ≥ 20%, n (%) 6 (4.32)European LeukemiaNet; NA: not applicable; CE: clonal evolution; WB
15.83%) died due to disease progression. Previous therapy
ncluded interferon in sixty-four patients (46.04%), hydrox-
urea in 131 patients (94.24%) and busulfan in one patient
0.72%). Eighty-four patients (60.4%) had intervals between
ML diagnosis and treatment with imatinib > 12 months.
here were 128 patients with cytogenetic tests available and
9 patients with molecular tests available. Among them,
6 patients (54.7%) achieved MCR, with 67 (48%) attained a
omplete cytogenetic response and nine (6.7%) partial cytoge-
etic response; 26 patients (18.7%) achieved major molecular
esponse (MMR). Thirty patients (21.59%) progressed to BP and
ve patients (3.6%) underwent HSCT.
Forty-one patients (29.5%) had CE. Among these patients,
3 had complex karyotypes, seven had trisomy of chromo-
ome 8, three had duplication of the Philadelphia chromo-
ome, four had chromosome 7 alterations, one had isochro-
osome 17q and 11 had other minor route chromosomal
berrations.14 Thirty-eight (27.34%) had splenomegaly; 28
20.14%) had anemia; 29 (20.86%) had platelets > 1000 × 109/L
r <100 × 109/L unresponsive to therapy; six (4.32%) had PB
9asophils ≥ 20%, ten (7.19%) had WBC  > 100 × 10 /L and 13
9.35%) had PB blasts 10–29% (Table 2).
Risk factors for poor survival by bivariate analysis
ncluded WBC  > 100 × 109/L (p-value = 0.1496), PB blasts 10–29%ite blood cell; PB: peripheral blood; BM: bone marrow.
(p-value = 0.009), PB basophils ≥ 20% (p-value = 0.04), Grades
3–4 hematologic toxicity (p-value = 0.0001), hemoglobin <Clonal evolution (%) 41 (29.5)
WBC ≥ 100 × 109/L, n (%) 10 (7.35)
PB: peripheral blood; WBC: white blood cell.
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Table 3 – Factors associated with lower survival rates in 139 accelerated phase chronic myeloid leukemia patients treated
with imatinib.
Variable Bivariate analysis p-Value Multivariate analysis p-Value
OR 95% CI OR 95% CI
PB blasts 10–29% 4.46 1.31–15.13 0.009 4.21 1.18–14.96 0.023
Hemoglobin < 10 g/dL 2.51 1.04–6.02 0.033 2.59 1.03–6.54 0.044
Grades 3 and 4 hematologic toxicity 4.29 1.89–9.76 <0.001 3.84 1.72–8.59 0.001
OR: odds ratio; 95% CI: 95% conﬁdence interval; PB: peripheral blood.
Figure 1 – Survival estimates according to the presence of
prognostic factors for progression to blast phase. Unbroken
line: patients with no prognostic factors (n = 46); dashed
line: patients with one prognostic factor (n = 68, Cox
regression: p-value = 0.04); dotted line: patients with two or
more prognostic factors (n = 25, Cox regression:
achieve statistical signiﬁcance (p-value = 0.250; HZ = 1.93; 95%
CI = 0.63–5.93) (Figure 5).3–4 hematologic toxicity [p-value = 0.001; odds ratio (OR)
of 3.84; 95% conﬁdence interval (95% CI) of 1.72–8.59], PB
blasts 10–29% (p-value = 0.023; OR of 4.21; 95% CI, 1.18–14.96)
and hemoglobin < 10 g/dL (p-value = 0.044; OR of 2.59; 95% CI,
1.03–6.54) remained signiﬁcant (Table 3).
Risk factors for lack of MCR  by bivariate analysis were
hemoglobin < 10 g/dL (p-value = 0.002), PB blasts 10–29%
(p-value = 0.006), platelets > 1000 × 109/L or <100 × 109/L (p-
value = 0.088), splenomegaly (p-value = 0.128), basophils
>20% (p-value = 0.032), Grades 3–4 hematologic toxicity (p-
value = 0.023), High Sokal score (p-value = 0.048), and previous
use of interferon (p-value = 0.041). In forward multivariate
analysis, only hemoglobin < 10 g/dL (p-value = 0.001; OR of
5.27; 95% CI, 1.98–14.07), PB blasts 10–29% (p-value = 0.007;
OR of 6.84; 95% CI, 1.68–27.89) and previous use of interferon
(p-value = 0.032; OR of 2.38; 95% CI, 1.08–5.24) were identiﬁed
as signiﬁcant (Table 4).
Risk factors for progression to BP by bivariate analy-
sis were hemoglobin < 10 g/dL (p-value = 0.003), high Sokal
score (p-value = 0.064), PB blasts 10–29% (p-value = 0.052),
WBC  > 100 × 109/L (p-value = 0.024), time from CML diagno-
sis to treatment with imatinib > 12 months (p-value = 0.014),
and basophils > 20% (p-value = 0.007). In forward multivari-
ate analysis, only hemoglobin < 10 g/dL (p-value = 0.005; OR of
3.94; 95% CI, 1.53–10.15), basophils > 20% (p-value = 0.023; OR
of 7.77; 95% CI, 1.32–45.62) and time from CML diagnosis to
treatment with imatinib > 12 months (p-value = 0.030; OR of
3.12; 95% CI, 1.11–8.75) remained signiﬁcant (Table 5). Patients
with one (p-value = 0.040; hazard ratio [HR] of 2.60; 95% CI of
1.04–6.49) and two or more  risk factors for progression to BP (p-
value < 0.001; HR of 5.52; 95% CI, 2.14–14.25) had lower survival
compared with patients who did not have any of these factors
(Figure 1).
As the PB blasts cut-off point varies in existing criteria, this
study analyzed PB blasts as a continuum with death as the
endpoint. The PB blast cut-off point, based on the ROC curve,
was 3% with a sensitivity of 46.5% and speciﬁcity of 89.8%.
After a median follow-up of 39 months (range: 3.4–129
months), 69.23% of the patients were alive. The OS was 66% at 5
years (Figure 2). The ﬁve patients submitted to HSCT were cen-
sored in the OS. Of those ﬁve patients, four remain alive and in
profound molecular response. One patient, who relapsed after
transplant and received therapy with imatinib, also achieved
profound molecular response. For the patients who achieved
MCR, DFS was 83% at 5 years (Figure 3). MCR  correlated
with better OS (p-value < 0.001; HR = 7.49; 95% CI = 3.62–15.52)
(Figure 4).p-value < 0.001).
Twenty-six (18.71%) patients lost molecular response and
17 (12.23%) patients lost cytogenetic response. Patients who
achieved MMR  had slightly better DFS rates compared with
those who did not reach MMR, but the difference did notFigure 2 – Overall survival.
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Table 4 – Risk Factors for not achieving major cytogenetic response of 139 accelerated phase chronic myeloid leukemia
patients treated with imatinib.
Variables Bivariate analysis p-Value Multivariate analysis p-Value
OR 95% CI OR 95% CI
PB blasts 10–29% 5.71 1.42–23.03 0.006 6.84 1.68–27.89 0.007
Hemoglobin < 10 g/dL 3.88 1.52–9.94 0.002 5.27 1.98–14.07 0.001
Previous use of IFN 2.12 1.01–4.42 0.041 2.38 1.08–5.27 0.032
OR: odds ratio; 95% CI: 95% conﬁdence interval; PB: peripheral blood; IFN: interferon.
Table 5 – Factors associated with progression to blast phase in 139 accelerated phase chronic myeloid leukemia patients
treated with imatinib.
Variables Bivariate analysis p-Value Multivariate analysis p-Value
OR 95% CI OR 95% CI
Time between CML Dx and Rx with imatinib > 12 months 3.27 1.21–8.85 0.014 3.12 1.11–8.75 0.03
PB basophils ≥ 20% 8.08 1.33–49.18 0.007 7.77 1.32–45.62 0.023
Hemoglobin < 10 g/dL 3.79 1.48–9.69 0.003 3.94 1.53–10.15 0.005
OR: odds ratio; 95% CI: 95% conﬁdence interval; Dx: diagnosis; Rx: treatme
Figure 3 – Disease Free Survival.
Figure 4 – Overall survival according to major cytogenetic
response (Cox regression; p-value < 0.001). Unbroken line:
major cytogenetic response (n = 76); dashed line: failure to
achieve major cytogenetic response (n = 52).nt; PB: peripheral blood.
Discussion
As AP-CML criteria vary in the literature, the current pop-
ulation was studied to evaluate prognostic factors for poor
survival, lack of MCR and progression to BP. Published criteria
as well as other clinically relevant factors were considered.
Regarding the primary endpoint, parameters of poor sur-
vival were Grades 3–4 hematologic toxicity, high blast counts,
and low hemoglobin concentration. No statistical signiﬁcance
was found for platelets or CE. Kantarjian et al. reported
pretreatment hemoglobin < 10 g/dL and a lack of cytogenetic
response after three months on imatinib therapy as nega-
tive predictors of survival in AP-CML.15 Similar risk factors
were identiﬁed by Jiang et al., who reported that CML  dura-
tion before treatment > 12 months, hemoglobin < 10 g/dL and
PB blasts > 5% were independent adverse prognostic factors for
Figure 5 – Disease Free Survival according to major
molecular response (Cox regression; p-value = 0.250).
Unbroken line: Major molecular response (n = 26); dashed
line: failure to achieve major molecular response (n = 53).
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Table 6 – Published results of imatinib therapy for
accelerated phase chronic myeloid leukemia patients.
MDACC14 Jiang et al.15 Palandri et al.7 Current study
n 176 87 111 139
MCR 43% 49% 30% 54.7%
MMR – 34.5% – 18.7%
OS 53% (4y) 51.4% (6y) 43% (7y) 66% (5y)
MDACC: M. D. Anderson Cancer Center; MCR: major cytogenetic
r
1999;340(17):1330–40.response; MMR: major molecular response; OS: overall survival.
both OS and progression-free survival.16 Interestingly when
the blast percentage was analyzed as a continuous variable a
cut-off point of 3% in the PB was identiﬁed as a predictor of
poor survival, suggesting that lower values of PB blasts can be
of prognostic value.16
Hematological toxicity with imatinib is more  frequent in
the late stages of the disease. Severe pancytopenia developed
by some patients may indicate an exhaustion of the normal
clone with disease progression. Some authors had previously
identiﬁed hematologic toxicity after tyrosine kinase inhibitor
therapy as a risk factor for survival.17,18
Risk factors for not achieving MCR were
hemoglobin < 10 g/dL, PB blasts > 5%, and previous use of
interferon. As treatment with imatinib compared favorably
with the results of treatment using interferon and other
therapies in AP-CML patients,15 it seems that delaying the
most effective therapy was the explanation that previous
use of interferon was a negative factor for MCR. The Gruppo
Italiano Malattie EMatologiche dell’Adulto (GIMEMA) CML
Working Party found that a stable and conﬁrmed complete
cytogenetic response to imatinib constitutes an affordable
surrogate marker of long-term OS and DFS, even among
AP-CML patients.7
Predictors of progression to BP were hemoglobin < 10 g/dL,
basophils ≥ 20%, and time from diagnosis to therapy > 12
months. The deﬁnition of BP used in this study was 30% or
more blasts in order to include every patient that would be
classiﬁed as in AP by at least one published criterion. The low
number of patients limited the possibility of further categoriz-
ing patients by blast percentage in multivariate analysis and
that is a limitation of the present study. An increased basophil
count is one of the risk factors identiﬁed as signiﬁcant for OS
and DFS by Hoffmann et al., and it was used to calculate the
European Treatment and Outcome Study (EUTOS) score.19
The rates of MCR  and MMR  in this study were 54.7% and
18.7%, respectively, and thus similar to previous articles6,7,15
(Table 6). CML  duration > 12 months and hemoglobin < 10 g/dL
were independent adverse predictors of DFS.16 As for the MMR,
there was a small number of patients with available molecular
tests, and this could explain the lack of signiﬁcance of MMR
on the DFS rate, although a trend was identiﬁed. The Sokal
risk score has been reported to predict molecular response
and OS.20 Moreover, Tripathi et al. identiﬁed a correlation
between an increased total leukocyte count and poor cytoge-
netic response.21 However, in this study, the Sokal score and
hyperleukocytosis were not associated with progression to BP.
CE and age were clinical factors not signiﬁcantly associated
with either the primary or secondary endpoints. Although 2 0 1 5;3  7(5):341–347
some authors suggest that CE is not an important factor
for achieving MMR or complete cytogenetic response with
imatinib therapy,22 it is an independent poor prognostic fac-
tor for survival in both CP-CML and AP-CML according to
others.23 Regarding age, older patients treated with imatinib
were reported by some authors as having worse survival, but
not by others.24,25 According to Cortes et al., age was not found
to be an independent poor prognostic factor for achieving cyto-
genetic response and for survival in AP-CML patients.26
As mentioned before, Jiang et al. demonstrated that CML
duration before treatment ≥12 months, hemoglobin < 100 g/L,
and PB blasts ≥ 5% were risk factors for survival among AP
patients with CML. Patients were classiﬁed into low risk (if they
had none of the factors), intermediate risk (if they had one fac-
tor), or high risk (for those with at least 2 factors).16 Allogeneic
HSCT gives signiﬁcant survival advantages only for high and
intermediate-risk patients with AP-CML. For low risk patients,
imatinib therapy leads to a similar outcome as HSCT.16
This study provides long-term results of survival and
response of a cohort of AP-CML patients treated with imat-
inib. The ﬁve-year OS of 60% and DFS of 75% among those
who achieved MCR are reassuring results, which indicate that
patients who lack identiﬁed risk factors can achieve long-term
response with imatinib.
Prospective studies are very important to deﬁne which is
the best therapy for this population. Thus, identifying risk fac-
tors can allow for tailored therapy with the aim of improving
survival, which is usually poor in advanced stage CML.
Conclusion
These data indicate that patients with Grades 3–4 hemato-
logic toxicity after therapy with imatinib, PB blasts 10–29%,
and hemoglobin < 10 g/dL, had worse survival than some other
patients also classiﬁed as AP. Lack of MCR  was associated
with hemoglobin < 10 g/dL, PB blasts 10–29%, and previous
use of interferon. Whereas progression to BP was correlated
with hemoglobin < 10 g/dL, PB basophils ≥ 20%, and time from
CML diagnosis to treatment with imatinib > 12 months. This
information can allow for tailored therapy with the aim of
improving results, which are usually poor in advanced stage
CML.
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